

## Index

Note: Page numbers of article titles are in **boldface** type.

- Ambulatory monitoring, in myocardial infarction, 39–41  
  nuclear techniques in, 91–92
- Aminophylline, in myocardial infarction, 51–52
- Amiodarone, in myocardial infarction, in sustained arrhythmia, 41
- Ammonia, N-13 labeled, as imaging agent, in myocardial infarction, 88–89
- Analgesics, in myocardial infarction, 29–36
- Anatomic implantable cardioverter defibrillator, in arrhythmia treatment, 42–43
- Anemic infarct, histologic appearance of, 2  
  reperfusion therapy and, 11
- Aneurysm, ventricular, arrhythmias and, 39  
  nuclear imaging of, 83–84  
  surgery on, 42
- Angina, post-infarction, 165–172  
  definition of, 165  
  mortality and, 165  
  pathophysiology of, 165–167  
  prevalence of, 165  
  risk stratification and, 157–158  
  sudden death risk and, 40  
  treatment of, 167–170  
    antithrombotic agents in, 168–169  
    conservative vs. aggressive approach in, 170  
    coronary artery bypass in, 169–170  
    intra-aortic balloon pump in, 169  
    pharmacological, 167–168  
    vs. pericarditis, 167  
  unstable. See also *Angina, post-infarction*.  
    atherosclerotic plaque fissure and, 8–9
- Angiocardiography, radionuclide, in ventricular functional evaluation, 81–84
- Angioplasty, coronary. See also *Percutaneous transluminal coronary angioplasty*.  
  effects of, 12–14  
  in post-infarction angina, 169
- Anisoyated plasminogen streptokinase, in myocardial infarction, 125
- Antiarrhythmic therapy, in myocardial infarction, in sustained arrhythmia, 41  
  indications for, 38  
  sudden death risk and, 39–40
- Anticoagulants, after myocardial infarction, 175  
  in myocardial infarction, 111–118  
  after thrombolysis, 130–131  
  early trials of, 111–112  
  pulmonary embolism and, 112–113  
  randomized trials of, 112  
  risks of, 116  
  systemic embolization and, 113–116  
  thrombolysis with, 132–133  
  in post-infarction angina, 168–169
- Antitachycardia pacemaker, after myocardial infarction, 43
- Arrhythmias. See also specific arrhythmia; *Ventricular arrhythmias*.  
  in myocardial infarction, bradyarrhythmias, 49–61  
  surgery for, 41–42
- Arteriography, coronary, in myocardial infarction, risk stratification and, 160  
  in post-infarction angina, 169
- Aspartate transaminase (AST), in myocardial infarction, 97, 103–104
- Aspirin, after myocardial infarction, 175–177  
  in post-infarction angina, 169  
  in thrombosis prevention, 120
- AST (aspartate transaminase), in myocardial infarction, 97, 103–104
- Asystole, in myocardial infarction, 54
- Atenolol, in post-infarction angina, 169
- Atherosclerotic plaque, fissure of, in myocardial infarction, 8–9  
  hemorrhage within, after reperfusion therapy, 14  
  rupture of, 119–120
- Atrioventricular block, in myocardial infarction, 17–18, 50–52
- Atropine, in myocardial infarction, 50, 64
- Autonomic disturbances, in myocardial infarction, 64–65  
  treatment of, 64–65
- Balloon pump. See *Intra-aortic balloon; Percutaneous transluminal coronary angioplasty*.
- BB CK (creatinine kinase BB isoenzyme), 98–99, 103
- Beta-blockers, after myocardial infarction, 173–175  
  in myocardial infarction, causing sinus node dysfunction, 50  
  in autonomic disturbances, 64  
  in post-infarction angina, 168
- Blood flow, coronary, atherosclerotic plaque formation and, 119–120  
  reestablishment of. See also *Reperfusion therapy*.  
  in thrombolysis, 125–126
- Blood pressure abnormalities. See *Hypertension; Hypotension*.
- Bradyarrhythmias, in myocardial infarction, 49–61  
  AV nodal block, 50–52  
  bundle branch block, 52–58  
  distal conduction system disease, 52–59  
  incidence of, 49  
  non-AV nodal block, 52–58  
  pacemaker in, 58–59  
  sinus node dysfunction, 49–50  
  treatment of, 64

- Bretylum, in myocardial infarction, during ventricular arrhythmia, 38
- Bundle branch block, in myocardial infarction, 52-59  
arrhythmias and, 39
- Calcium channel blockers, after myocardial infarction, 175  
in myocardial infarction, causing sinus node dysfunction, 50  
in post-infarction angina, 168
- Cardiac arrest, in myocardial infarction, caused by antiarrhythmic therapy, 41
- Cardiac enzymes. *See Enzymes, cardiac.*
- Cardiac rupture, in myocardial infarction, 70-72
- Cardiogenic shock, in myocardial infarction, 22-23, 66-67  
of right ventricle, 68
- Cardiomyopathy, coronary dilated, in myocardial infarction, 23-24
- Cardioverter, anatomic implantable, in arrhythmia treatment, 42-43
- Catheter ablation, in ventricular tachycardia, after myocardial infarction, 43
- Catheterization, cardiac. *See Percutaneous transluminal coronary angioplasty.*
- Chordae tendineae, rupture of, in myocardial infarction, 19
- Coagulation necrosis, in myocardial infarction, 3
- Computed tomography, SPECT technique, in myocardial infarction, 86-87
- Contraction band necrosis, in myocardial infarction, 3
- Coronary angioplasty. *See also Percutaneous transluminal coronary angioplasty.*  
effects of, 12-14  
in post-infarction angina, 169
- Coronary arteries, obstruction/occlusion of, clinical events in, 121  
pathophysiology of, 119-121  
vs. myocardial infarction location, 4-5  
reocclusion of, after thrombolysis, 130-131  
prevention of, 132-133  
spasm of, in unstable angina, 166  
thrombus in, formation of, at atherosclerotic plaque, 8-9  
in myocardial infarction, 5-8, 140
- Coronary arteriography, in post-infarction angina, 169  
risk stratification and, 160
- Coronary artery bypass, in arrhythmia treatment, 42  
in myocardial infarction, percutaneous transluminal coronary angioplasty and, 147-148  
in post-infarction angina, 169-170
- Coronary dilated cardiomyopathy, in myocardial infarction, 23-24
- Creatine kinase, assays of, 99-102  
based on charge differences, 100-101  
for isoenzymes, 100-102  
for total activity, 99-100
- BB isoenzyme of, 98-99, 103  
chemical properties of, 97-98  
forms of, 98  
in myocardium, 98  
in serum, 99  
in skeletal muscle, 98  
isoenzyme distribution of, 98-99  
macro, 99  
MB isoenzyme of, assays for, 100-102  
infarct size determination with, 104  
myocardial infarction diagnosis with, 102-106  
properties of, 98  
subforms of, 104-106  
tissue distribution of, 98  
mitochondrial, 98  
MM isoenzyme of, subforms of, 104-106
- Defibrillator, anatomic implantable cardioverter, in arrhythmia treatment, 42-43
- Dicoumarol, in myocardial infarction, 111
- Diltiazem, after myocardial infarction, 175  
in post-infarction angina, 168
- Dipyridamole, after myocardial infarction, 175, 177  
in nuclear imaging, 90
- Dobutamine, in myocardial infarction, 75  
right ventricular, 70
- Dopamine, in myocardial infarction, 75
- Edema, pulmonary, in myocardial infarction, treatment of, 65-66
- Elderly patients, lidocaine side effects in, 38
- Electrocardiography, signal averaged, in myocardial infarction, 40
- Electrophoresis, in creatine kinase isoenzyme assay, 100-101
- Electrophysiologic study, in myocardial infarction, 40-41
- Embolism, pulmonary, in myocardial infarction, anticoagulation and, 112-113  
systemic, in myocardial infarction, anticoagulation and, 113-116
- Enzymes, cardiac, 97-109  
assays for, 99-102  
AST, 103-104  
chemical properties of, 97-98  
clinical applications of, 105  
in infarct size determination, 104  
in myocardial infarction diagnosis, 102-103, 105-106  
in reperfusion diagnosis, 106-107  
isoenzyme tissue distribution of, 98-99  
LDH, 103-104  
properties of, as MI marker, 97  
subforms of, 104-107
- Equilibrium radionuclide angiocardigraphy, in myocardial infarction, 81-84
- Esmolol, in post-infarction angina, 168
- Exercise testing, nuclear techniques and, 159-160  
perfusion imaging in, 84  
risk stratification and, 158-160  
thallium-201 imaging in, 90-91  
ventricular arrhythmias induced in, 156-157
- Fatty acids, control of, after myocardial infarction, 173  
metabolism of, in myocardial infarction, 87-88
- Fibrillation, ventricular. *See Ventricular fibrillation.*
- Fibrinolytic therapy. *See Thrombolysis.*
- First pass radionuclide angiocardigraphy, in myocardial infarction, 81-84
- "Flash" pulmonary edema, in myocardial infarction, 65-66
- Glucose metabolism, evaluation of, in myocardial infarction, 88
- Healing, of myocardial infarct, 3
- Heart, rupture of, clinical features of, 70-71  
pathogenesis of, 70  
therapy of, 72

- Heart block, in myocardial infarction, 17-18, 50-59  
 arrhythmias and, 39  
 complete, 54-56
- Hemodynamic instability, in myocardial infarction. See under *Myocardial infarction*.
- Hemorrhage, in thrombolytic therapy, 127-128
- Hemorrhagic infarction, histologic appearance of, 3  
 reperfusion therapy and, 9-14
- Heparin, in myocardial infarction, 111, 113, 116  
 after thrombolysis, 131  
 thrombolysis with, 132  
 in post-infarction angina, 168-169
- Hypertension, in myocardial infarction, cardiac rupture and, 71  
 thrombolytic therapy contraindicated in, 127  
 treatment of, 64-65
- Hypotension, in myocardial infarction, treatment of, 64
- Immunoassay, in creatine kinase isoenzyme assay, 101-102
- Infarct, after original infarct(s), 16  
 anemic, histologic appearance of, 2  
 reperfusion therapy and, 11  
 ectopic, 5  
 expansion of, 11, 14-16  
 cardiac rupture and, 70  
 nuclear imaging of, 83-84  
 extension of, 16  
 localization of, perfusion imaging in, 85  
 of right ventricle. See under *Ventricle, right*.  
 size determination of, with cardiac enzymes, 104
- "Infarct artery," AV nodal block and, 51-52  
 blood flow reestablishment in, in thrombolysis, 125-126  
 condition of, after reperfusion therapy, 14  
 intraplaque hemorrhage in, 14  
 obstruction of, vs. myocardial infarction location, 4-5
- Infarct avid imaging, in myocardial infarction, 86-87
- Intra-aortic balloon, in acute mitral regurgitation, 73  
 in myocardial infarction, 75-76  
 in cardiogenic shock, 67  
 right ventricular, 70  
 in post-infarction angina, 169
- Intracranial bleeding, in thrombolytic therapy, 127-128
- Ischemia, in myocardial infarction, at distance from original infarct, 166  
 histologic changes in, 2  
 prediction of, 157-160
- Ischemic cardiomyopathy, in myocardial infarction, 23-24
- Ischemic pulmonary edema, in myocardial infarction, treatment of, 65-66
- Isoproterenol, in myocardial infarction, 50, 64
- Lactate dehydrogenase (LDH), in myocardial infarction, 97, 103-104
- Lidocaine, in myocardial infarction, during ventricular arrhythmia, 38
- MB CK. See under *Creatine kinase*.
- Meperidine, in myocardial infarction, 32
- Metabolic imaging, in myocardial infarction, 87-89
- Metoprolol, in post-infarction angina, 168
- MI See *Myocardial infarction*.
- Mitral regurgitation, in myocardial infarction, 72-73
- MM CK (creatinine kinase MM isoenzyme), subforms of, 104-106
- Monitoring, in myocardial infarction, ambulatory, 39-41  
 nuclear techniques in, 91-92
- Morphine, in myocardial infarction, 29-32
- Mortality, in myocardial infarction, 1, 153-154. See also *Risk stratification*.
- Myocardial infarction, acute mitral regurgitation in, 72-73  
 analgesic therapy in, 29-36  
 anemic infarct in, 2, 11  
 angina pectoris after, 165-172  
 definition of, 165  
 mortality and, 165  
 pathophysiology of, 165-167  
 prevalence of, 165  
 treatment of, 167-170
- anterior, 3  
 anticoagulants in. See *Anticoagulants*.  
 apical, 3  
 assessment of, with nuclear techniques. See *Nuclear techniques*.  
 AST in, 97, 103-104  
 asystole in, 54  
 atherosclerotic plaque fissure and, 8-9  
 autonomic disturbances in, 64-65  
 basal, 3  
 bundle branch block in, 52-59  
 cardiac enzymes in. See *Enzymes, cardiac*.  
 cardiac rupture in, 18-19, 70-72  
 cardiogenic shock in, 22-23, 66-67  
 complications of, 14-24  
 coronary angioplasty in, 12-14, 169. See also *Percutaneous transluminal coronary angioplasty*.  
 coronary arteries and. See under *Coronary arteries*.  
 coronary dilated cardiomyopathy in, 23-24  
 definition of, 1-2  
 diagnosis of, creatine kinase isoenzymes in, 102-103, 105-106  
 perfusion imaging in, 84-85  
 distal conduction system disease in, 52-59  
 healing in, 4  
 heart block in, 17-18, 50-59  
 complete, 54-56  
 hemodynamic instability in, prognosis and, 63  
 treatment of, 63-79  
 acute mitral regurgitation, 72-73  
 autonomic disturbances, 64-65  
 cardiac rupture, 70-72  
 cardiogenic shock, 22-23, 66-67  
 drugs in, 73-75  
 intra-aortic balloon pump in, 75-76  
 pulmonary edema, 65-66  
 right ventricular infarct, 67-70
- hemorrhagic infarct in, 3  
 reperfusion therapy in, 9-12  
 histologic changes in, 1-2  
 in atrium, 4  
 in mid-portion, 3  
 in right ventricle. See under *Ventricle, right*.  
 infarct expansion in, 14-16  
 infarct extension in, 16  
 infarct location in, 3-4  
 vs. "infarct artery," 4-5  
 infarct size determination in, with creatine kinase isoenzymes, 104  
 intra-aortic balloon in. See *Intra-aortic balloon*.  
 lateral, 3  
 LDH in, 97, 103-104  
 mortality in, 1, 153-154. See also *Risk stratification*.  
 myocytolysis in, 3  
 necrosis in, 1-3  
 nontransmural, 3  
 papillary muscle dysfunction in, 19-20

- Myocardial infarction (*Continued*)
- papillary muscle rupture in, 19
  - pathology of, 1–28
  - pathophysiology of, 140
  - pericarditis in, 16
  - pharmacotherapy in, 73–75. See also *Analgesics; Anti-coagulants*.
    - aminophylline, 51–52
    - antiarrhythmics, 38–41
    - atropine, 50, 64
    - beta-blockers, 50, 64
    - calcium channel blockers, 50
    - dobutamine, 70, 75
    - dopamine, 75
    - meperidine, 32
    - morphine, 29–32
    - nalbuphine, 33–34
    - narcotics, 29–34
    - nitroglycerine, 64, 74
    - nitroprusside, 64–65, 74–75
    - nitrous oxide, 34
    - pentazocine, 32–33
  - posterior, 3
  - prophylactic treatment after, 173–178
    - anticoagulation in, 175
      - beta-adrenergic blockers in, 173–175
      - calcium channel blockers in, 175
      - platelet-active drugs in, 175–177
  - pulmonary edema in, 65–66
  - reinfarction in, 16, 158
  - reperfusion therapy in. See *Reperfusion therapy*.
  - reversible ischemia in, 2
  - sequelae of, 14–24
  - sinus node dysfunction in, 49–50
  - streptokinase in. See *Streptokinase*.
  - therapy in, analgesic, 29–36
    - anticoagulants in, 111–118
      - in hemodynamic instability, 63–79
    - reperfusion. See *Reperfusion therapy*.
    - thrombolytic. See *Thrombolysis*.
  - transmural, 3
  - ventricular aneurysm in, 20, 83–84, 39
  - ventricular arrhythmias in. See *Ventricular arrhythmias*.
    - ventricular free wall rupture in, 18, 70–71
    - ventricular mural thrombus in, 22
    - ventricular septal rupture in, 18–19, 71–72
- Myocardial metabolic imaging, in myocardial infarction, 87–89
- Myocardial perfusion imaging, in myocardial infarction, 84–86
- Myocytolysis, in myocardial infarction, 3
- Nalbuphine, in myocardial infarction, 33–34
- Narcotics, in myocardial infarction, 29–34
- Necrosis, in myocardial infarction, coagulation type, 3
  - colliquative type (myocytolysis), 3
  - contraction band type, 3
  - definition of, 1–2
  - histologic changes in, 1–2
- Nifedipine, after myocardial infarction, 175
  - in myocardial infarction, in autonomic disturbances, 64–65
- Nitrates, in post-infarction angina, 167–168
- Nitroglycerine, in myocardial infarction, 74
  - in autonomic disturbances, 64
  - in post-infarction angina, 167–168
- Nitroprusside, in myocardial infarction, 74–75
  - in autonomic disturbances, 64–65
- Nitrous oxide, in myocardial infarction, 34
- Nonaneurysmal mural thrombus, in myocardial infarction, 22
- Non-Q wave infarction, reinfarction and, 158
- Nontransmural myocardial infarction, definition of, 3
- Nuclear techniques, myocardial infarction assessment with, 81–95
  - ambulatory monitoring in, 91–92
  - equilibrium radionuclide angiocardiology, 81–84
  - exercise testing and, 159–160
  - first pass radionuclide angiocardiology, 81–84
  - in acute phase, 81–89
    - in convalescent phase, 89–93
  - infarct avid imaging in, 86–87
  - metabolic imaging in, 87–89
  - perfusion imaging in, 84–86
  - risk stratification and, 159–160
- Pacemaker, after myocardial infarction, 43
  - in myocardial infarction, in distal conduction abnormalities, 58–59
    - permanent, in distal conduction abnormalities, 58–59
    - temporary prophylactic, 54–55, 57
- Pain management, in myocardial infarction, 29–36
- Papillary muscle, dysfunction of, in myocardial infarction, 19–20
  - rupture of, in myocardial infarction, 19
  - treatment of, 72–73
- Paradoxical coronary thrombosis, 5
- Pentazocine, in myocardial infarction, 32–33
- Percutaneous transluminal coronary angioplasty, in myocardial infarction, 139–152
  - after thrombolysis, 143–147
  - as primary perfusion modality, 143
  - complications of, 147
    - coronary artery bypass and, 147–148
    - rationale for, 141–143
    - with thrombolysis, 128, 130, 133
  - in post-infarction angina, 169
- Perfusion imaging, in myocardial infarction, 84–86
- Pericardial restraint, in right ventricular infarction, 69
- Pericarditis, in myocardial infarction, 16
  - vs. post-infarction angina, 167
- Persantine, after myocardial infarction, 177
- PET (positron emission tomography), in myocardial infarction, 87–89
- Plaque, atherosclerotic, fissure of, in myocardial infarction, 8–9
- Plasminogen activator, in myocardial infarction, 123–126, 131–132, 141
  - blood flow reestablishment and, 125–126
  - complications of, 130
    - left ventricular functional restoration, 127
- Platelet inhibition therapy, after myocardial infarction, 175–177
  - in reocclusion prevention, 133
- Platelet release reaction, in coronary artery thrombosis, 5–6
- Platelets, deposition of, in coronary artery occlusion, 120
  - in unstable angina, 166
- Positron emission tomography, in myocardial infarction, 87–89
- Practolol, after myocardial infarction, 174
- Premature ventricular contractions, in myocardial infarction, sudden death risk and, 39

- Pro-urokinase, in myocardial infarction, 124
- Procainamide, in myocardial infarction, during ventricular arrhythmia, 38
- Propranolol, after myocardial infarction, 173-175  
in post-infarction angina, 168
- Pulmonary congestion/edema, in myocardial infarction, 65-66  
risk stratification and, 160-161
- Pulmonary embolism, in myocardial infarction, anticoagulation and, 112-113
- Radionuclide techniques. See *Nuclear techniques*.
- Reinfarction, 16  
non-Q wave infarction and, 158
- Reperfusion therapy, in myocardial infarction, 9-14  
cardiac enzymes in, 106-107  
nuclear techniques and, 85  
percutaneous transluminal angioplasty in. See *Percutaneous transluminal coronary angioplasty*.  
thrombolytic. See *Thrombolysis*.
- Reverse redistribution, in thallium-201 imaging, 85
- Risk stratification, after myocardial infarction, 153-163  
historical aspects of, 153-154  
ischemia and, 157-160  
nuclear techniques in, 89-92  
risk variables competing with, 154-155  
ventricular arrhythmias and, 155-157  
ventricular function and, 160-161
- Rubidium-82 imaging, in myocardial infarction, 88-89
- Rupture, cardiac, clinical features of, 70-71  
diagnosis of, 71-72  
pathogenesis of, 70  
therapy of, 72  
of chordae tendineae, in myocardial infarction, 19  
of papillary muscle, in myocardial infarction, 19  
treatment of, 72-73  
ventricular free wall, in myocardial infarction, 18, 70-71  
ventricular septal, in myocardial infarction, 18-19, 71-72
- Septum, ventricular, rupture of, in myocardial infarction, 18-19, 71-72
- Shock, cardiogenic, in myocardial infarction, 22-23  
of right ventricle, 68  
treatment of, 66-67, 70-72
- Single chain urokinase-type plasminogen activator, in myocardial infarction, 124-125
- Single photon emission computed tomographic technique, in myocardial infarction assessment, 86-87
- Sinus arrest, in myocardial infarction, 49-50
- Sinus bradycardia, in myocardial infarction, 49-50
- Sinus exit block, in myocardial infarction, 49-50
- Sinus node dysfunction, in myocardial infarction, 49-50
- SPECT (single photon emission computed tomographic technique), in myocardial infarction, 86-87
- ST segment depression, in exercise testing, 158-159
- Streptokinase, in myocardial infarction, 9-10, 12-14, 121-123, 132  
blood flow reestablishment and, 125-126  
complications of, 130  
intracoronary administration of, 140-141  
left ventricular functional restoration, 126-127  
mortality rates in, 127-129  
in post-infarction angina, 168
- Subendocardial resection, in arrhythmia treatment, 42
- Sulfapyrazole, after myocardial infarction, 175, 177
- Surgery, in myocardial infarction. See also *Coronary artery bypass*.  
for arrhythmia, 41-42  
for cardiac rupture, 72  
for cardiogenic shock, 67  
in acute mitral regurgitation, 73
- Sympathetic overdrive, in myocardial infarction, treatment of, 64
- Tachycardia, in myocardial infarction, treatment of, 64  
ventricular. See *Ventricular tachycardia*.
- Tamponade, in cardiac rupture, 71
- Technetium-99m hexakis-methoxy-isobutyl isonitrile imaging, in myocardial infarction, 86
- Technetium-99m pyrophosphate imaging, in myocardial infarction, 86-87
- Thallium-201 imaging, in exercise testing, 90-91  
in myocardial infarction, 84-85  
risk stratification and, 159-160
- Thromboembolism, in myocardial infarction, anticoagulation and. See *Anticoagulants*.
- Thrombolysis, in myocardial infarction, 119-137  
agents for, 121-125. See also *Streptokinase*.  
assessment of. See also *Nuclear techniques*.  
blood flow reestablishment in, 125-126  
complications of, 129-130  
prevention of, 132  
current recommendations for, 131-133  
intracoronary, 140-141  
left ventricular functional restoration in, 126-127  
mortality in, 127-129  
occlusion pathophysiology and, 119-121  
patient selection for, 132  
percutaneous transluminal coronary angioplasty after, 143-147  
rationale for, 121  
reocclusion after, 130-131  
prevention of, 132-133  
in post-infarction angina, 168-169
- Thrombus/thrombosis, coronary, formation of, after arterial injury, 119-120  
at atherosclerotic plaque, 8-9  
in myocardial infarction, 5-8, 22, 140  
paradoxical, 5  
of left ventricle, anticoagulation and, 113-116  
ventricular mural, 22
- Timolol, after myocardial infarction, 174-175
- Tissue-type plasminogen activator, in myocardial infarction, 123-126, 141  
blood flow reestablishment and, 125-126  
complications of, 130  
left ventricular functional restoration and, 127  
in post-infarction angina, 168
- Transmural myocardial infarction, definition of, 3
- Urokinase, in myocardial infarction, 121-123
- Vagotonia, in myocardial infarction, treatment of, 64
- Vasodilators. See also *Nitroglycerine*.  
in myocardial infarction, 74-75  
in acute mitral regurgitation, 73

- Ventricle, function of, in myocardial infarction, nuclear techniques and, 81-84, 89-92  
risk stratification and, 160-161
- left, failure of, post-infarction angina and, 167  
functional compromise of, arrhythmias and, 39  
functional restoration in, by thrombolysis, 126-127  
thrombus of, anticoagulation and, 113-116
- right, infarction of, 3-4, 23  
clinical features of, 68  
diagnosis of, 69  
management of, 67-70  
nuclear imaging of, 82-83  
pathogenesis of, 68-69
- septum of, rupture of, in myocardial infarction, 18, 71-72
- wall of, rupture of, in myocardial infarction, 18
- Ventricular aneurysm, arrhythmias and, 39  
in myocardial infarction, 20, 22  
nuclear imaging of, 83-84
- Ventricular arrhythmias, in myocardial infarction, 37-47  
device therapy in, 42-43  
electrical monitoring in, 39-41  
first 48 hours of, 37-48  
risk stratification and, 155-157  
surgery in, 41-42
- sustained, 38-43  
prediction of, 39-40  
post-infarction angina and, 167
- Ventricular ectopy, in myocardial infarction, risk stratification and, 155
- Ventricular fibrillation, in myocardial infarction, 16-17  
management of, 38  
occurrence of, 37-38  
surgery for, 41-42  
time course of, 38-39
- Ventricular mural thrombus, in myocardial infarction, 22
- Ventricular premature contractions, in myocardial infarction, 16  
risk stratification and, 155-157
- Ventricular tachycardia, after myocardial infarction, pacemaker for, 43  
in myocardial infarction, catheter ablation of, 43  
management of, 38  
occurrence of, 37-38  
pharmacotherapy for, 41  
risk stratification and, 155-157  
surgery for, 41-42  
time course of, 38-39
- Ventriculography, in myocardial infarction, risk stratification and, 159-160